VERA — Vera Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1831828 ·
Last close
$34.26
Market Cap
$2.46B
52W High
$47.00
52W Low
$30.59
ADV30
1,077,137
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -125,132,000 | -121,032,000 | 621,739,000 | 114,351,000 | 122,042,000 |
| Dec 2025 | 0 | — | -94,206,000 | -91,097,000 | 734,733,000 | 354,725,000 | 130,212,000 |
| Sep 2025 | 0 | — | -83,932,000 | -80,293,000 | 517,503,000 | 57,773,000 | 118,623,000 |
| Jun 2025 | 0 | — | -80,141,000 | -76,531,000 | 578,528,000 | 49,121,000 | 110,251,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-241,104,000
Investing CF
$194,286,000
Financing CF
$308,897,000
CapEx
$-630,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-4.12
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-760,865,000
Inventory
—
Receivables
$3,285,000
ST Investments
$359,864,000
EBIT TTM
$-292,084,000
Pretax Income TTM
$-299,614,000
Interest Exp TTM
$7,530,000
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -315,473,000 | -299,615,000 | 734,733,000 | 130,212,000 | — | -241,104,000 |
| Dec 2024 | 0 | -167,170,000 | -152,148,000 | 655,681,000 | 78,526,000 | — | -134,679,000 |
| Dec 2023 | 0 | -102,012,000 | -95,990,000 | 175,546,000 | 73,861,000 | — | -92,181,000 |
| Dec 2022 | 0 | -90,903,000 | -89,056,000 | 131,435,000 | 54,527,000 | — | -67,596,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KLRA | Kailera Therapeutics, Inc. | $2.45B | $18.89 | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $2.40B | $51.89 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.40B | $24.35 | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.58B | $44.41 | — |
| IRON | Disc Medicine, Inc. | $2.60B | $67.99 | — |
News headlines (Yahoo Finance, 1h cache)
Will FDA Alignment on Atacicept’s eGFR Plan Reshape Vera Therapeutics’ (VERA) IgA Nephropathy Narrative
2026-06-08 20:10 · Yahoo
A Look At Vera Therapeutics (VERA) Valuation After FDA Alignment On Accelerated IgA Nephropathy Trial Analysis
2026-06-08 15:11 · Yahoo
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-05 20:05 · Yahoo
Sector Update: Healthcare Stocks Softer Late Afternoon
2026-06-02 19:45 · Yahoo
Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment
2026-06-02 16:51 · Yahoo
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
2026-06-02 11:00 · Yahoo
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing
2026-05-26 18:49 · Yahoo
The Bull Case For Vera Therapeutics (VERA) Could Change Following Atacicept’s FDA Priority Review And Ramp-Up
2026-05-11 01:09 · Yahoo
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-07 11:30 · Yahoo
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
2026-05-04 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.